by Biospring | May 30, 2022 | Curie Bio, EHR, Flatiron Health, Pharma, RWD, RWE, Zach Weinberg
Zach Weinberg is a Co-Founder of Curie Bio and Operator Partners. Zach was previously Co-Founder, President, and COO of both Flatiron Health (acquired by Roche in 2018 for $2B) and Invite Media (acquired by Google in 2010 for $81M). Zach is one of the most successful...
by Biospring | Apr 26, 2022 | Data Science, Digital Health, Drug Development, Drug Discovery, Janssen, Najat Khan
We were delighted to host a discussion with Najat Khan, PhD, Chief Data Science Officer and Global Head of Strategy and Operations, Janssen Research & Development (R&D), Johnson and Johnson. As the Chief Data Science Officer, Dr. Khan leads a team of 100+ data...
by Biospring | Apr 26, 2022 | Artificial Intelligence, Data, Drug Discovery, Health Care, John Baldoni, Pharma
We recently hosted a discussion with Dr. John Baldoni, one of Biospring’s Operational Experts. He is the Co-Founder and Chief Scientific Officer of SaponiQx, a recently formed vaccine discovery and development company. He’s also the CEO of the Atom...
by Biospring | Apr 26, 2022 | Amazon, Biospring Partners, CIC Health, COVID-19, Health Care, Maulik Majmudar, Rodrigo Martinez, Telehealth, Vaccines
We recently hosted a discussion with Dr. Maulik Majmudar, Cardiologist and Principal Medical Officer at Amazon and Rodrigo Martinez, Chief Marketing and Experience Officer at CIC Health. Maulik and Rodrigo shared their unique perspective on how healthcare has changed...
by Biospring | Apr 26, 2022 | Astrazeneca, Biospring Partners, COVID-19, Economy, Jay Bradner, Katie Burke, Novartis, Oxford, Peter B. Henry, Return to work, Sir John Bell, Vaccines
Last December, we hosted a discussion with industry leaders on COVID-19 and Vaccines, Return-to-Work, and the Economy. We were delighted to host Dr. Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Biospring’s advisors Sir...
